These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38846086)

  • 1. Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease.
    Brownjohn PW; Zoufir A; O'Donovan DJ; Sudhahar S; Syme A; Huckvale R; Porter JR; Bange H; Brennan J; Thompson NT
    Front Pharmacol; 2024; 15():1397864. PubMed ID: 38846086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion.
    Wilk EJ; Howton TC; Fisher JL; Oza VH; Brownlee RT; McPherson KC; Cleary HL; Yoder BK; George JF; Mrug M; Lasseigne BN
    Mol Med; 2023 May; 29(1):67. PubMed ID: 37217845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tolvaptan, a vasopressin V
    Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles.
    Malas TB; Leonhard WN; Bange H; Granchi Z; Hettne KM; Van Westen GJP; Price LS; 't Hoen PAC; Peters DJM
    EBioMedicine; 2020 Jan; 51():102585. PubMed ID: 31879244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
    Liu F; Feng C; Shen H; Fu H; Mao J
    Kidney Dis (Basel); 2021 Sep; 7(5):343-349. PubMed ID: 34604341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
    Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
    Raina R; Houry A; Rath P; Mangat G; Pandher D; Islam M; Khattab AG; Kalout JK; Bagga S
    Drug Healthc Patient Saf; 2022; 14():147-159. PubMed ID: 36105663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment.
    Lee Y; Blount KL; Dai F; Thompson S; Scher JK; Bitterman S; Droher M; Herzog EL; Moeckel G; Karihaloo A; Dahl NK
    Clin Exp Nephrol; 2018 Aug; 22(4):906-916. PubMed ID: 29453607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism-based approaches for autosomal dominant polycystic kidney disease.
    Bakaj I; Pocai A
    Front Mol Biosci; 2023; 10():1126055. PubMed ID: 36876046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug repurposing in autosomal dominant polycystic kidney disease.
    Zhou JX; Torres VE
    Kidney Int; 2023 May; 103(5):859-871. PubMed ID: 36870435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report.
    Pellegrino AM; Annicchiarico Petruzzelli L; Riccio E; Pisani A
    BMC Nephrol; 2019 Nov; 20(1):426. PubMed ID: 31752750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary exosome proteomic profiling defines stage-specific rapid progression of autosomal dominant polycystic kidney disease and tolvaptan efficacy.
    Raby KL; Horsely H; McCarthy-Boxer A; Norman JT; Wilson PD
    BBA Adv; 2021; 1():100013. PubMed ID: 37082007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.
    Soroka S; Alam A; Bevilacqua M; Girard LP; Komenda P; Loertscher R; McFarlane P; Pandeya S; Tam P; Bichet DG
    Can J Kidney Health Dis; 2017; 4():2054358117695784. PubMed ID: 28321325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Manifestation and Management of ADPKD in Western Countries.
    Sommerer C; Zeier M
    Kidney Dis (Basel); 2016 Oct; 2(3):120-127. PubMed ID: 27921039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic Kidney Disease Drug Development: A Conference Report.
    Liebau MC; Mekahli D; Perrone R; Soyfer B; Fedeles S
    Kidney Med; 2023 Mar; 5(3):100596. PubMed ID: 36698747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic approaches to autosomal dominant polycystic kidney disease.
    LaRiviere WB; Irazabal MV; Torres VE
    Transl Res; 2015 Apr; 165(4):488-98. PubMed ID: 25438190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.